The Future of Polycythemia Vera Treatment: Examining Besremi, Jakafi, and Rusfertide

 


Polycythemia Vera Treatment Landscape

Jakafi (Ruxolitinib), developed by Incyte, is an FDA-approved drug for the treatment of Polycythemia Vera. Jakafi is a JAK1/JAK2 inhibitor that works by reducing the overactive signaling of JAK1 and JAK2, which are associated with the symptoms of Polycythemia Vera. Jakafi’s patent expiration date is in 2027, but several companies have filed for generics. However, there might be a delay in the entry of generics due to legal disputes.

PharmaEssentia’s new entrant, entry into NCCN guidelines, insights on pricing, and launches

Besremi (Ropeginterferon alfa-2b) is a new entrant in the Polycythemia Vera market, developed by PharmaEssentia. It is a subcutaneous injection and has a different mode of action than Jakafi. Besremi is an interferon alpha-2b derivative that regulates the immune system and bone marrow, which can help control the overproduction of blood cells in Polycythemia Vera. Besremi was approved in the EU in 2020 and received FDA approval in the US in 2021. It has also been included in the National Comprehensive Cancer Network (NCCN) guidelines for the treatment of Polycythemia Vera. The pricing of Besremi is yet to be revealed, and the launch is expected in 2021.

Protagonist therapeutics’ Rusfertide: Uncertainty in uptake even with promising results?

Rusfertide (PTG-300) is an investigational drug developed by Protagonist Therapeutics for the treatment of Polycythemia Vera. Rusfertide is a hepcidin mimetic that regulates iron metabolism and controls erythropoiesis, which could help treat anemia in Polycythemia Vera. Rusfertide has shown promising results in clinical trials, and Protagonist has plans for its commercialization. However, the drug recently faced a setback as the FDA withdrew its Breakthrough Therapy Designation (BTD) due to concerns about the design of ongoing clinical trials. The uncertainty about Rusfertide’s approval could affect its uptake in the Polycythemia Vera market.


In conclusion, the Polycythemia Vera market has seen some significant developments in recent years, with the approval of new drugs like Besremi and investigational drugs like Rusfertide. The entry of generics for Jakafi might face some legal disputes, which could delay their launch. The pricing of Besremi is yet to be revealed, and its launch is expected soon. The uncertainty about the approval of Rusfertide could affect its uptake in the Polycythemia Vera market. However, with the availability of new drugs and emerging therapies in Polycythemia Vera, the Polycythemia Vera market is expected to grow in the coming years.

Related Reports

B Cell Chronic Lymphocytic Leukemia Market

DelveInsight's "B Cell Chronic Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Chronic Lymphocytic Leukemia, historical and forecasted epidemiology as well as the B Cell Chronic Lymphocytic Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


B-Cell Lymphomas Market

DelveInsight's "B-Cell Lymphomas Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Lymphomas, historical and forecasted epidemiology as well as the B-Cell Lymphomas market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Behcet’s Syndrome Market 

DelveInsight’s “Behcet’s Syndrome Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Behcet’s syndrome in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom.


Neoantigen-based Personalized Cancer therapeutic Vaccines 

DelveInsight’s “Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035” report delivers an in-depth understanding of the Neoantigen based Personalized Cancer therapeutic Vaccines and the Neoantigen-based personalized cancer therapeutic vaccines emerging market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Glioblastoma Multiforme Market

DelveInsight's "Glioblastoma Multiforme Market Insights, Epidemiology and Market Forecast– 2032" report delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.


Latest Reports By DelveInsight

Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market


To know more about our Consulting Services, Click here: DelveInsight Healthcare Consulting

Recent Blog’s By DelveInsight:

Comments

Post a Comment

Popular posts from this blog

Evaluating the Major Growth and Ongoing Developments in the Alpha-1 Antitrypsin Deficiency (AATD) Market

Image
  Alpha-1 Antitrypsin Deficiency Treatment Landscape Public health has contributed significantly to the understanding and control of diseases in the twenty-first century. Sometimes monitoring and treating a serious ailment still depends on an early diagnosis. Alpha-1 antitrypsin deficiency (AATD ) , one of these uncommon genetic disorders, has seen improvements in terms of awareness and factors taken into account during treatment. Alpha 1 antitrypsin, a beneficial enzyme inhibitor, is depleted in AATD, a hereditary disorder that results in lung damage and functional loss. The other pathology causes the AAT protein to misfold (gain-of-function), which decreases the amount of AAT and increases liver proteolytic stress. Due to the fact that this condition is inherited, those who inherit two copies of the defective gene are more likely to experience a variety of comorbidities. Approximately 80% of those who are impacted, according to published medical data, acquire lung disease. Alpha-1 an
Read more

Unleashing the Market Potential: A Comprehensive Analysis of Omega-3 Products

Image
Omega-3 fatty acids have gained significant attention in recent years due to their numerous health benefits. As a result, the demand for Omega-3 products has been on the rise, making it a promising market with immense potential. In this blog post, we will explore the importance of Omega-3 for the body, its key benefits, potential risks, market dynamics, key companies in the industry, and provide a comprehensive analysis and perspective on this growing market. Why is Omega-3 Important for the body? Omega-3 fatty acids are essential nutrients that play a crucial role in maintaining overall health. They are not produced naturally by the body and therefore must be obtained through diet or supplements. Omega-3s are known for their anti-inflammatory properties and are vital for supporting brain health, heart function, and reducing the risk of chronic diseases. What are the key benefits of Omega-3? The benefits of Omega-3 fatty acids are diverse and significant. Research suggests that they
Read more

Harnessing the Power of Immunomodulators: Applications and Implications

Image
Immunomodulators have emerged as crucial components in the field of medicine, gaining increasing attention for their ability to regulate and modify the immune system's responses. These agents play a pivotal role in treating a diverse range of conditions, from autoimmune diseases and cancer to infectious diseases and organ transplants. By modulating immune responses, immunomodulators offer promising avenues for addressing unmet medical needs. What are the Major Types of Immunomodulators? Immunomodulators encompass various types of medications and therapies designed to influence immune system activity. They include anti-inflammatory medications, cytokinesis regulators , and antiretroviral therapies. These agents act on different pathways within the immune system, offering targeted approaches for managing conditions such as allergies, rheumatoid arthritis, and infectious diseases. What are the Key Applications of Immunomodulators? The applications of immunomodulators span across mul
Read more